Tianfeng Securities: The board of directors of Hubei Hongtai Group has agreed to acquire 7.85%equity of the company held by Renfu Pharmaceutical

On July 25, 2022, Tianfeng Securities (601162.SH) issued an announcement of the company's shareholders' agreement transfer.

The announcement shows that Tianfeng Securities has recently received the decision of the board of directors of Hubei Hongtai Group Co., Ltd. (hereinafter referred to as Hongtai Group). 7.85%equity and corresponding fund sources of Tianfeng Securities.

The announcement disclosed that on March 31, 2022, Tianfeng Securities held more than 5%of the shareholders Fu Pharmaceutical and Hongtai Group signed the "Stock Transfer Agreement on the Effective Effective Stocks of Tianfeng Securities". In the form of agreement transfer, 680 million shares of Tianfeng Securities shares held to Hongtai Group (accounting for 7.85%of the current total share capital of Tianfeng Securities).

The transfer price of the target shares is the calculation of 90%of the closing price of Ri Tianfeng Securities. The transfer unit price is 3.123 yuan/share, and the total transfer price of the target shares is 2.124 billion yuan.

It is understood that since 2022, it has been in Human Fu Pharmaceutical, Wuhan Contemporary Technology Industry Group Co., Ltd. (hereinafter referred to The "contemporary department" represented by the special Worker Group Co., Ltd. (hereinafter referred to as the three special cables) has been reducing holdings of Tianfeng Securities.

As early as the 7.85%shares of Tianfeng Securities' transfer of Tianfeng Securities, on February 25, 2022, the three special cable channels had reduced their holdings of 19.77 million shares through the major transaction method, and the reduction ratio was 0.23%by 0.23%. ; From February 25th, 2022 to February 28, 2022, contemporary groups also reduced their holdings of 114 million shares through large transactions, with a reduction of 1.31%.

Tianfeng Securities said that after the above -mentioned changes in equity, Renfu Pharmaceutical will hold 0 shares of the company, accounting for 0%of the company's total share capital; The proportion of shares holding Tianfeng Securities has decreased by more than 5%.

(Tianfeng Securities)

At the same time, Hongtai Group Tianfeng Securities shares will increase to 680 million shares, accounting for 7.85%of the total share capital of Tianfeng Securities.

According to public information, Hongtai Group is a wholly state -owned commercial platform enterprise supervised and managed by the Hubei Provincial Government. Life and other financial institutions have more than ten financial licenses such as local AMC, private equity funds, commercial factoring, financial leasing, financing guarantee, and small loans, and initially formed a full -license financial control group structure for financing resources in the province.

As of December 31, 2021, Hongtai Group's total assets were 61.9 billion yuan, net assets were 210 yuan, operating income in 2021 was 14.1 billion yuan, and net profit was 532 million yuan.

It is understood that in recent years, Tianfeng Securities has been interested in improving the national financial weight in the equity structure. In April 2021, the 8.18 billion yuan targets completed by Tianfeng Securities include Guangdong Hengjian, Qu Jiangkong, Wuhan, Wuhan, Wuhan, and Wuhan. The central enterprise and local state -owned platform, including the State -owned Assets of Xi'an Free Trade Port, and Sichuan, also attracted securities firms such as Galaxy, Shen Wanhongyuan, open source securities, Donghai Securities, Federal Securities, etc. A total of 15 institutions such as public offerings and insurance capital participated.

The company's 2021 annual report disclosed that as of the end of 2021, China ’s top ten shareholders of Tianfeng Securities accounted for 68.52%of capital. If the equity transfer is completed, the shareholders of Tianfeng Securities will increase to 89.18%.

- END -